First Trust Nasdaq Pharmaceuticals ETF
FTXH
31 hedge funds and large institutions have $18.1M invested in First Trust Nasdaq Pharmaceuticals ETF in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 7 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
3.28% more ownership
Funds ownership: 52.1% → 55.38% (+3.3%)
9% less funds holding
Funds holding: 34 → 31 (-3)
18% less capital invested
Capital invested by funds: $22M → $18.1M (-$3.9M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$835K |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$517K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
+$395K |
| 4 |
WFA
WMG Financial Advisors
Knoxville,
Tennessee
|
+$305K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$226K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Truist Financial
Charlotte,
North Carolina
|
-$4.89M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.23M |
| 3 |
CA
Cetera Advisors
Denver,
Colorado
|
-$550K |
| 4 |
Goldman Sachs
New York
|
-$550K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$206K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $46K | -$8.5K | -317 | -15% |
|
|
HI
27
Harbour Investments
Madison,
Wisconsin
| $21.8K | – | – | – |
|
|
ADL
28
Asset Dedication LLC
San Francisco,
California
| $15K | – | – | – |
|
|
IA
29
IFP Advisors
Tampa,
Florida
| $6.6K | – | – | – |
|
|
HCM
30
Hollencrest Capital Management
Newport Beach,
California
| $940 | – | – | – |
|
31
Wells Fargo
San Francisco,
California
| $29 | – | – | – |
|
|
CS
32
Credit Suisse
Zurich,
Switzerland
| – | -$1.23M | -44,800 | Closed |
|
|
CA
33
Cetera Advisors
Denver,
Colorado
| – | -$550K | -20,053 | Closed |
|
|
34
Goldman Sachs
New York
| – | -$550K | -20,039 | Closed |
|
|
LFG
35
Larson Financial Group
St Louis,
Missouri
| – | -$27.7K | -1,008 | Closed |
|
|
MCC
36
Money Concepts Capital
Palm Beach Gardens,
Florida
| – | -$11.5K | -418 | Closed |
|
|
GI
37
Gradient Investments
Arden Hills,
Minnesota
| – | -$10.3K | -375 | Closed |
|
|
MWM
38
MinichMacGregor Wealth Management
Saratoga Springs,
New York
| – | -$3.15K | -115 | Closed |
|
FTXH Hedge Fund Activity: Q1 2023 in Review
31 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q1 2023, worth a combined $18.1M — down 18% from $22M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of FTXH and 4 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 14 added.
The largest buyer was Susquehanna International Group, adding an estimated $835K. The largest seller was Truist Financial, cutting an estimated $4.89M.
- 31 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q1 2023, down from 34 in Q4 2022.
- Funds reported $18.1M of First Trust Nasdaq Pharmaceuticals ETF stock for Q1 2023, down 18% quarter-over-quarter.
- 4 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q1 2023 and 7 closed out, a net change of -3 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q1 2023 was Susquehanna International Group, an estimated $835K added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q1 2023 was Truist Financial, an estimated $4.89M sold.
Based on aggregated 13F filings for Q1 2023.